FWM
PVCT

Frontier Wealth Management’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Frontier Wealth Management’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-20,000
Closed -$16K – 335
2014
Q4 		$16K Buy
+20,000
New +$18.3K ﹤0.01% 268

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Frontier Wealth Management's PVCT Position: Q1 2015 in Review

Frontier Wealth Management sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q1 2015, closing a stake of 20,000 shares — an estimated $16K sold.

Frontier Wealth Management first reported a position in PVCT in Q4 2014 and held it in 1 quarter. The position peaked at $16K in Q4 2014. 35 funds tracked by Wall St. Rank hold PVCT as of Q1 2015.

  • Frontier Wealth Management reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q1 2015 after selling out during the quarter.
  • Frontier Wealth Management sold 20,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q1 2015, an estimated $16K.
  • Frontier Wealth Management first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2014 and held it in 1 quarter.
  • Frontier Wealth Management's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $16K in Q4 2014.
  • 35 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q1 2015.

Based on Frontier Wealth Management's 13F filing for Q1 2015, filed 14 May 2015.